Nasdaq: DNTH

Dianthus Therapeutics, Inc. (DNTH)

Dianthus Therapeutics, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker DNTH. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
DNTH
Exchange
Nasdaq
SEC CIK
1690585
Official filings
SEC EDGAR

Research DNTH

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Dianthus Therapeutics, Inc.'s stock ticker?

Dianthus Therapeutics, Inc. trades under the ticker symbol DNTH on Nasdaq. Its SEC Central Index Key (CIK) is 1690585.

Where can I read Dianthus Therapeutics, Inc.'s SEC filings?

The DNTH SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Dianthus Therapeutics, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze DNTH's financial statements?

The DNTH Financials page shows Dianthus Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does DNTH compare with its peers and the market?

The DNTH Peer Comparison page lines Dianthus Therapeutics, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.